Quality — cash generation, balance sheet, moat, management. The judgement that separates a name from a business.
Neil Woodford has been answering questions about investing for 35 years – and every one of them comes down to seven decisions. In part one of this three-part series, Neil and Jon Adair cover the funnel: the three decisions that take you from every company in the world down to a shortlist worth owning.
Investment decisions shouldn’t be driven by emotion or FOMO, but by thoughtful analysis and valuation. In this article, I share my approach to evaluating businesses, understanding uncertainty, and finding undervalued opportunities that others might overlook.
UK stocks are being taken private at a record pace: this year, takeover bids for London-listed companies have run at roughly £60bn against under £600m raised in new IPOs, and Neil Woodford argues that this wave of M&A is the clearest sign in years that UK equities are undervalued. In this episode, Woodford and Jon Adair break down why the FTSE and London stock market trade at such a deep discount to the US, what a 75% takeover premium reveals about UK share prices, whether British stocks are cheap or a value trap, and where Woodford sees value across UK banks, oil and housebuilders.
This week, a single American memory chip company became worth more than AstraZeneca, HSBC and Shell combined. So why has Britain never built one of its own?
UK banks remain structurally undervalued despite solid performance. I explain why I believe the discount persists—and why it might finally be about to close.
AI demand is soaring. Inventories are clearing. Pricing power is returning. And that’s showing up in the numbers — not just in Nvidia, but in less obvious names like STMicro and TSMC.
UK housebuilders are out of favour. But that’s exactly when companies often offer the best long-term opportunities.
After years of weak performance in the biotech sector, BioNTech has secured a landmark partnership with Bristol Myers Squibb, worth up to $11.1bn. This deal is a major validation of BioNTech’s cancer pipeline and supports Neil’s thesis: the market is undervaluing mature biotech firms. BioNTech was up 20% yesterday on the news.
Trump’s presidency has already sparked dramatic changes—not just in politics but in the corporate world. From free speech to ESG and DEI, this article explores how his election is reshaping global business culture and raising questions about honesty, accountability, and the future of capitalism.
Jaguar’s bold rebrand and shift to an all-electric lineup by 2026 have sparked intrigue and criticism. European carmakers are racing to adapt to EVs, fierce competition, and shifting customer attitudes.
